Elanco Animal Health Incorporated research snapshot
ELAN AI stock analysis currently reads Elanco Animal Health as a global pet and farm animal health company rebuilding growth through innovation products, channel execution, and debt paydown after years of integration and leverage overhang. As of the July 10, 2026 close at $24.82, the stock has a verified market cap near $12.40 billion on about 499.45 million shares. Trailing GAAP results still show a loss, with TTM EPS near -$0.49, while adjusted earnings, Q1 2026 organic growth, and product launches such as Zenrelia and Befrena are the bull case drivers. The ELAN AI stock forecast uses scenario ranges rather than a single price call because leverage, competition with Zoetis and other animal health peers, product uptake, and multiple compression can change outcomes quickly.
Current price
$24.82
Market cap
$12.40 billion verified market cap
AI score
64 / 100
Rating
Innovation-led animal health recovery with leverage and GAAP profitability risk
Trend status
Mildly constructive, trading above the 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Elanco sells parasiticides, vaccines, therapeutics, and other animal health products to pet owners, veterinarians, and livestock producers worldwide. | High |
| Moat | Brand reach, veterinary relationships, regulatory know-how, and a broader product portfolio support the franchise, but competition from Zoetis and other animal health companies keeps pricing and share contested. | Medium |
| Management | CEO Jeff Simmons has steered the post-spin and Bayer Animal Health integration phase toward innovation launches and leverage reduction; the current test is turning growth into cleaner cash returns. | Medium-high |
| Financial trend | FY2025 revenue was $4.715 billion, up about 6% year over year, while reported net loss was $232 million. Q1 2026 revenue of $1.371 billion rose 15% with adjusted EPS of $0.40. | High |
| Valuation | At $24.82, ELAN screens near 1.91x book value, about 2.53x sales, 39.4x free cash flow per share, and roughly 23x forward earnings, while TTM GAAP PE is not meaningful because EPS is negative. | High |
| Technical trend | The stock is above the 50-day average near $23.37 and the 200-day average near $23.03, with RSI near 55.96 and a 52-week range of $13.39 to $27.72. | Medium |
| Risk level | Main risks are elevated leverage, product launch underperformance, competition, farm animal demand swings, short interest near 7% of shares, and continued GAAP losses. | Medium-high |
| AI confidence | Descriptive confidence is high because key figures were cross-checked. Return confidence is lower because adjusted-to-GAAP conversion and competitive product uptake remain uncertain. | High data confidence |
| Investment certainty | ELAN has improving operational momentum, but the price still needs sustained innovation revenue, leverage progress, and cleaner earnings quality to create a wide margin of safety. | Medium |
ELAN AI stock forecast
The ELAN AI stock forecast is scenario-based because trailing GAAP EPS is negative and the equity story depends on adjusted earnings growth, product launches, and leverage reduction. Using the $24.82 price reference, a $1.06 adjusted EPS base, and an audited three-year model, the mechanical outcomes are about $40.80 in a bullish case, $26.70 in a base case, and $12.70 in a bearish case before any dividend, which Elanco does not currently pay.
$36 to $42 before dividends
More likely if innovation revenue tracks toward the $1.2 billion 2026 target, Zenrelia, Befrena, and parasiticide brands take share, net leverage falls toward 3.0x to 3.2x and then lower, and the market re-rates adjusted earnings toward the mid-20s PE range.
$24 to $29 before dividends
More likely if revenue grows mid- to high-single digits, adjusted EPS stays near company guidance around $1.03 to $1.09 for 2026 with modest growth after that, and investors keep valuing ELAN near a high-teens to low-20s earnings multiple.
$10 to $15 before dividends
More likely if product launches disappoint, farm animal demand softens, competition forces pricing pressure, leverage stays elevated, free cash flow weakens, or the market compresses the multiple toward distressed animal health levels.
ELAN AI technical analysis
ELAN AI technical analysis is mildly constructive as of the July 11, 2026 data cutoff. StockAnalysis showed a July 10 close of $24.82, a 50-day moving average near $23.37, a 200-day moving average near $23.03, RSI near 55.96, 20-day average volume near 4.61 million shares, and a 52-week range of $13.39 to $27.72.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $24.82 | StockAnalysis listed the July 10, 2026 close at $24.82 after a day range of $24.12 to $25.08. |
| Immediate support | $23.00 to $23.40 | This area brackets the 50-day average near $23.37 and the 200-day average near $23.03 and is the first trend-support zone to watch. |
| Deeper support | $19.50 to $20.50 | A deeper pullback zone where prior consolidation after the 2025 rebound could reassert itself if the short-term trend fails. |
| Near resistance | $26.50 to $27.00 | This is the next reaction zone below the recent high where short-term buyers need follow-through volume. |
| Upper resistance | $27.50 to $28.00 | This range sits near the 52-week high of $27.72 and is the key breakout area for the current recovery swing. |
| Moving averages | 50-day near $23.37, 200-day near $23.03 | A close above both moving averages keeps the rebound intact, while a break below both would weaken momentum quickly. |
| Momentum | RSI near 55.96 | Momentum is constructive but not overbought, which fits a grind higher rather than an exhausted spike. |
| Volume | 20-day average near 4.61 million shares | Volume confirmation matters around earnings, product updates, and leverage commentary because ELAN can move sharply on growth and debt news. |
| Volatility | Watch August 5, 2026 earnings and short interest | The next earnings update, innovation revenue progress, and short interest near 7.12% of shares can amplify swings around key levels. |
| Invalidation | Close below $23.00, then below $20.00 | A sustained break below the clustered moving averages weakens the rebound. A break toward $20 would challenge the larger recovery setup. |
ELAN AI trading strategy
The ELAN AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with innovation revenue, pet and farm mix, competitive product uptake, free cash flow, net leverage, and GAAP versus adjusted earnings quality.
Watch for ELAN to hold above the $23.00 to $23.40 support area and press through $26.50 to $27.00 with improving innovation revenue, stable adjusted margins, and no new leverage or competitive shock.
A failed breakout followed by a close below $23.00 should reduce trend confidence, especially if management signals weaker product uptake or slower debt reduction.
If ELAN pulls back toward $20 without a permanent earnings reset, compare the lower price with free cash flow per share near $0.63, net leverage progress, and the durability of adjusted EPS guidance.
Do not treat a pullback as automatically attractive if leverage rises again, free cash flow weakens, or competition erodes the innovation pipeline thesis.
Track pet health growth, farm animal demand, Zenrelia and Befrena launch metrics, adjusted EBITDA margin, free cash flow conversion, net debt, net leverage ratio, short interest, and the gap between GAAP and adjusted results.
Position sizing should reflect that animal health stocks can look cheap on forward multiples before leverage, competitive pricing, or product delays reprice the equity.
Investment research summary
Customers pay Elanco because pet owners, veterinarians, and livestock producers need parasiticides, vaccines, therapeutics, and related animal health products that protect animal welfare and farm productivity.
The moat comes from brand portfolio breadth, veterinary relationships, regulatory expertise, manufacturing scale, and an expanding innovation stack. The moat is real but not unassailable, especially against Zoetis and other global animal health competitors.
The thesis fails if new products underdeliver, competition compresses pricing, farm animal demand weakens, leverage stays too high for too long, or free cash flow cannot convert adjusted profits into durable balance-sheet repair.
Jeff Simmons has focused the company on innovation-led growth and debt paydown after the Bayer Animal Health integration. The current management test is proving that growth can coexist with cleaner earnings quality and lower net leverage.
Animal health sits inside multi-year demand for pet medicalization, livestock productivity, vaccines, and dermatology or parasiticide innovation. The offset is competitive intensity and the fact that farm animal cycles can still create earnings volatility.
At $24.82, ELAN is not priced like a distressed asset, but it is also not a deep-value GAAP earnings story. Margin of safety improves if innovation revenue lands, leverage falls toward or below 3.0x, and free cash flow stays positive while multiples remain reasonable.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $24.82 July 10, 2026 close | StockAnalysis ELAN quote | July 11, 2026 |
| Market cap and shares | $12.40 billion market cap, 499.45 million shares; 10-Q showed 499,449,583 shares outstanding as of May 1, 2026 | StockAnalysis statistics and Elanco Q1 2026 10-Q | July 11, 2026 |
| FY2025 revenue | $4.715 billion, up 6.22% year over year | StockAnalysis financials, Macrotrends, and Elanco FY2025 results | July 11, 2026 |
| FY2025 net income | Reported net loss of $232 million | StockAnalysis financials and Elanco FY2025 results | July 11, 2026 |
| Q1 2026 operating snapshot | Revenue $1.371 billion, adjusted EPS $0.40, adjusted EBITDA $334 million, net leverage 3.5x | Elanco Q1 2026 results | July 11, 2026 |
| Cash and debt | About $428 million cash and $4.30 billion total debt on StockAnalysis; company net debt near $3.3 billion at Q1 2026 | StockAnalysis balance sheet and Elanco Q1 2026 results | July 11, 2026 |
| Free cash flow | TTM free cash flow about $315 million, or $0.63 per share | StockAnalysis cash flow and statistics | July 11, 2026 |
| Valuation ratios | 1.91x P/B, about 2.53x sales, 39.4x P/FCF, forward PE near 22.96; TTM PE not meaningful on -$0.49 EPS | Pineify financial_rigor.py calculation from StockAnalysis inputs | July 11, 2026 |
| CEO | Jeff Simmons, President and CEO | Elanco investor communications | July 11, 2026 |
| Technical levels | 50-day MA near $23.37, 200-day MA near $23.03, RSI near 55.96, 52-week range $13.39 to $27.72 | StockAnalysis ELAN technical data | July 11, 2026 |
This ELAN AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of July 11, 2026 and may be wrong if product launches, leverage, competition, valuation multiples, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
